• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Do Amniocentesis or CVS Really Lead to Increased Risk of Miscarriage? 

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • More recent cohort population studies and RCTs suggest that previous risk for miscarriage following prenatal invasive genetic testing may be overstated
  • Salomon et al. (Ultrasound in Obstetrics & Gynecology, 2019) sought to estimate procedure-related risk of miscarriage after amniocentesis and chorionic villus sampling (CVS)

METHODS:

  • Systematic review and updated meta-analysis
  • Inclusion criteria
    • RCTs | Prospective or retrospective cohort or case-control studies
    • Results included complications following CVS or amniocentesis and pregnancy loss <24 weeks 
  • Data analysis
    • Procedure-related risk of miscarriage was estimated as a weighted (based on sample size of each study) risk difference
    • Subgroup analysis also performed

RESULTS:

  • 20 controlled studies were included
  • Risk of miscarriage after amniocentesis
    • Miscarriage group: Risk of pregnancy loss of 0.91% (95% CI, 0.73 –1.09)
    • Control group: Pooled loss rate of 0.58% (95 CI%, 0.47–0.70)
    • Pooled weighted procedure-related risk of miscarriage: 0.30% (95% CI, 0.11–0.49)
    • Using only studies with similar patient risk profiles: Procedure related risk was 0.12% (95% CI, -0.05 to 0.30)
  • Risk of miscarriage after CVS
    • Groups
    • CVS group: a risk of pregnancy loss of 1.39% (95% CI, 0.76–2.02)
    • Control group: Risk of pregnancy loss of 1.23% (95 CI%, 0.86–1.59)
    • Pooled weighted procedure-related risk of miscarriage: 0.20% (95% CI, -0.12 to 0.52)
    • Using only studies with similar patient risk profiles: Procedure related risk was was -0.1 (95% CI, -0.29 to 0.08)

CONCLUSION:

  • When studies are restricted to patients with similar risk profiles, the authors conclude

…amniocentesis is associated with a procedure-related risk of 1:300 at most, or more likely, no significant increase in risk

With regard to CVS, our results demonstrate that, there is no significant procedure-related risk associated with undertaking this procedure

  • The authors suggest a few reasons why CVS may be safer than amniocentesis including
    • CVS performed by trained MFM experts
    • Amniotic sac is a ‘closed cavity’ vs the highly vascular placenta at 12 weeks
    • When CVS is more challenging, the operator may choose to defer to amniocentesis, thus biasing amniocentesis toward more difficult cases

Learn More – Primary Sources:

Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of the literature and updated meta‐analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Should Amniocentesis or Chorionic Villus Sampling Be Offered to All Pregnant Women?
Does Noninvasive Screening Result in Fewer Miscarriages When Compared to Amniocentesis?
Fetal loss after amnio or CVS – what is the risk ?
Invasive Testing: Are All Centers Seeing a Similar Steep Decline in Procedures?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site